Top N.Y.-Based Hospitals Join Pfizer Research Venture
Top N.Y.-Based Hospitals Join Pfizer Research Venture [The Day, New London, Conn.]
From Day, The (New London, CT) (January 26, 2011)
Jan. 26--Pfizer Inc. said Tuesday that seven New York City-based medical centers have joined its newly established research initiative called the Centers for Therapeutic Innovation.
The top research hospitals joining the initiative include Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center and the Albert Einstein College of Medicine of Yeshiva University. Others are Rockefeller University, New York University Langone Medical Center and Weill Cornell Medical College. Pfizer has said in the past that scientists from Groton and New London might be called on to contribute ideas an expertise to the collaboration, which targets major academic institutions nationwide to work on schemes for discovering important new drugs.
"Together with these outstanding academic medical centers, we will more effectively delve into the deep science of disease with the goal of developing novel targets that can be applied to meet patients’ needs," Anthony Coyle, head of the initiative, said in a statement.
Pfizer also announced that it would lease research space at the Alexandria Center for Life Science, the only science park in New York City, as a way to "facilitate close working relationships between Pfizer and its academic partners."
The first of Pfizer’s academic innovation centers, at the University of California-San Francisco, was announced in November. The collaboration is based in Cambridge, Mass.
Pfizer has said in the past that scientists outside the academic-research teams will be encouraged to contribute ideas to the collaboration and may be called upon to add their expertise to a given project. In addition, academic researchers may spend time in Pfizer laboratories such as the one in Groton, the company has said. "The Centers for Therapeutic Innovation partnerships mimic a venture capital-funded biotechnology start-up, whereby Pfizer funds pre-clinical and clinical development programs, offers equitable intellectual property and ownership rights to support continued experimentation and exploration, as well as broad rights to publication," Pfizer said in a statement. The partnerships "will more closely connect academia and the pharmaceutical industry with an aim toward greater productivity, shared risk and a deep connection to science."
To see more of The Day, or to subscribe to the newspaper, go to http://www.theday.com.
Copyright (c) 2011, The Day, New London, Conn.
Distributed by McClatchy-Tribune Information Services.
For more information about the content services offered by McClatchy-Tribune Information Services (MCT), visit www.mctinfoservices.com, e-mail email@example.com, or call 866-280-5210 (outside the United States, call +1 312-222-4544)
Posted: January 2011